Buy or sell ViaCyte stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
ViaCyte Stock
Preclinical Therapeutic Company
About ViaCyte Stock
ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Funding History
| May 2006 | $20.0M |
|---|---|
| July 2007 | $25.0M |
| July 2013 | $10.6M |
| August 2014 | $20.0M |
| August 2014 | $5.4M |
| September 2014 | $16.6M |
| July 2016 | $3.9M |
| May 2017 | $10.0M |
| September 2018 | $10.0M |
| November 2018 | $80.0M |
Management
Senior Vice President, Science & Technology
Allan Robins
Vice President, Business Development and Strategy
Mark Zimmerman
Director
Steven R. Altman
President and Chief Executive Officer
Paul Laikind
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
